AMICUS THERAPEUTICS INC (FOLD)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for FOLD
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| FOLD | Chair of the Board of Directors | 65 | ["Retired from Merck & Company after 26 years", "President of Global Vaccines and Infectious Disease", "President, U.S. Hospital and Specialty Products", "Chief Executive Officer and President of The International AIDS Vaccine Initiative", "Executive leadership roles in global and U.S. marketing, sales, and managed care", "Chair of the Board of HCU Network America", "Trustee of University at Buffalo Foundation", "Holds a B.S. in Pharmacy and a M.B.A. in Marketing", "Honorary doctorate in sciences from the State University of New York at Buffalo"] | ["Compensation and Leadership Development"] | 2025 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NVAX | [] | ["Nominating and Corporate Governance Committee"] | 2026 | ||
| APD | Retired President, Merck & Co. Inc. Global Vaccine and Infectious Disease Division and Retired President and Chief Executive Officer of International AIDS Vaccine Initiative; Director | 60 | ["Extensive experience in government relations and public policy", "International marketing", "Mergers and acquisitions", "Talent management", "Expertise in productivity", "Deep understanding of the healthcare business"] | ["Corporate Governance", "Nominating", "Management Development", "Compensation"] | 2019 |
| VRTX | Nominee | 51 | ["Former President, Vaccines and Infectious Diseases Merck & Co., Inc.", "Former President, Vaccines and Infectious Diseases of Merck & Co., Inc.", "Various marketing, sales and managed care roles at Merck since 1983", "Member of the board of directors for Air Products and Chemicals, Inc. and Amicus Therapeutics, Inc.", "National Industrial Advisory Committee at University at Buffalo School of Pharmacy and Pharmaceutical Sciences"] | [] | 2011 |
Biography sourced from the proxy statement filing.
Margaret G. McGlynn has served as a member of the Board since October 2009. She retired from Merck & Company, Inc. (NYSE: MRK) ( Merck ), a multinational pharmaceutical company, after 26 years and serving in roles including President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales, and managed care. Following her retirement from Merck, Ms. McGlynn served as Chief Executive Officer and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn serves as Chair of the Board of Directors of Novavax, Inc. (Nasdaq: NVAX). Previously, she served on the Boards of Vertex Pharmaceuticals Inc. (Nasdaq: VRTX), Air Products and Chemicals, Inc. (NYSE: APD) and Orphan Technologies Ltd. She is also Chair of the Board of HCU Network America, a non-profit which provides advocacy and supports research for patients affected by the rare disease homocystinuria, and is a Trustee of University at Buffalo Foundation. Ms. McGlynn holds a B.S. in Pharmacy and a M.B.A. in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo. Skills and Qualifications: Ms. McGlynn has significant leadership experience in the pharmaceutical industry, including her service as a senior executive of Merck where she led commercialization across several therapeutic areas and geographies and managed large organizations. This experience, combined with her service on biopharmaceutical company boards and a rare disease patient advocacy organization, gives her important insights into Amicus s business and a comprehensive understanding of compensation management and the relationship of compensation practices to the organization and its development, which contributed to our conclusion that she should continue to serve as a director of the Company, Chair of the Compensation and Leadership Development Committee, and a member of the Nominating and Corporate Governance Committee.